Summary
Many bone diseases, such as osteoporosis affect 55 percent of people over 50 years of age. Researchers at the University of Nebraska Medical Center have developed a new therapeutic agent by modifying cyclodextrin to target bones. This molecule can be used therapeutically to prevent or treat bone disorders by stimulating bone anabolic activity. This technology could be helpful to millions of people world wide and could help prevent injuries suffered from bone diseases.

Market Value
A method of prevention and treatment that can increase bone density and prevent fractures would be extremely beneficial worldwide.

Features and Benefits

• Targets bone adsorbing diseases, including osteoporosis and periodontis.
• Can be used as both prevention and treatment.
• May be used to deliver antibiotic, anti-inflammatory, or anesthetic drugs to the bone.
• Increases growth/mass of bone.

Application Filed

(TID - 03)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.